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Novelty and impact: Our study compares invasive cervical cancer (ICC) rates among women 
living with HIV who initiated antiretroviral therapy (ART) across different geographic regions. 
It shows that ICC incidence rates are particularly high in women living with HIV in South 
Africa or Latin America. ICC prevention through early ART initiation, equitable access to 
effective cervical cancer screening, and promotion of human papillomavirus vaccination 
should be key elements of global efforts to reduce cancer-related health inequities. 
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Abbreviations: aHR, adjusted hazard ratio; ART, antiretroviral therapy; CI, confidence 
interval; COHERE, Collaboration of Observational HIV Epidemiological Research in Europe; 
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Abstract 
We compared invasive cervical cancer (ICC) incidence rates in Europe, South Africa, 
Latin and North America among women living with HIV who initiated antiretroviral therapy 
(ART) between 1996 and 2014. We analyzed cohort data from the International epidemiology 
Databases to Evaluate AIDS (IeDEA) and the Collaboration of Observational HIV 
Epidemiological Research in Europe (COHERE) in EuroCoord. We used flexible parametric 
survival models to determine regional ICC rates and risk factors for incident ICC. We included 
64,231 women from 45 countries. During 320,141 person-years (pys), 356 incident ICC cases 
were diagnosed (Europe 164, South Africa 156, North America 19, Latin America 17). Raw ICC 
incidence rates per 100,000 pys were 447 in South Africa (95% confidence interval [CI] 382-
523), 136 in Latin America (95% CI 85-219), 76 in North America (95% CI 48-119), and 66 in 
Europe (95% CI 57-77). Compared with European women ICC rates at 5 years after ART 
initiation were more than double in Latin America (adjusted hazard ratio [aHR]  2.43, 95% CI 
1.27-4.68) and 11-times higher in South Africa (aHR 10.66, 95% CI 6.73-16.88), but similar in 
North America (aHR 0.79, 95% CI 0.37-1.71). Overall, ICC rates increased with age (>50 years 
versus 16-30 years, aHR 1.57, 95% CI 1.03-2.40) and lower CD4 cell counts at ART initiation 
(per 100 cell/µl decrease, aHR 1.25, 95% CI 1.15-1.36). Improving access to early ART initiation 
and effective cervical cancer screening in women living with HIV should be key parts of global 
efforts to reduce cancer-related health inequities.  
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Introduction 
Vast global inequities in the burden of invasive cervical cancer (ICC) exist.1,2 While 
access to effective screening and treatment of pre-cancerous cervical lesions has substantially 
reduced the risk of developing ICC in high-income countries, ICC remains a common cause of 
premature mortality and morbidity in women in low- and middle-income countries.1,2 ICC 
disproportionally affects women living with human immunodeficiency virus (HIV), who are 
more likely to have persistent co-infection with high-risk human papillomavirus (HPV) types,3 
to develop pre-cancerous cervical lesions,4 and to progress to ICC than HIV-negative women.4 
The advent and scale-up of combination antiretroviral therapy (ART) has led to a dramatic 
decline in morbidity and mortality from many HIV-associated diseases,5 but these decreases 
have not occurred for ICC.6,7 Indeed, as life expectancy after starting ART increases, there is 
more time for pre-cancerous cervical lesions to develop into ICC, but early initiation of ART 
seems to lower HPV co-infection rates and improve control of pre-cancerous cervical lesions.8  
Global inequities in ICC incidence rates among women living with HIV have not been 
assessed previously. Our aim was to assess such inequities by comparing ICC incidence rates 
across different geographic regions among women who had initiated ART. Additionally, we 
examined risk factors for developing ICC in these women.  
 
Methods 
Databases 
We analyzed routinely collected clinical, demographic, laboratory, and treatment data 
of women enrolled in observational HIV cohorts that participate in the International 
epidemiology Databases to Evaluate AIDS (IeDEA) or the Collaboration of Observational HIV 
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Epidemiological Research in Europe (COHERE) in EuroCoord. IeDEA has regional data centers 
in the Asia-Pacific, Australia, North America, Latin America and four African regions. Cohorts 
from the following IeDEA regions initially contributed data to this study: the North American 
AIDS Cohort Collaboration on Research and Design (NA-ACCORD),9 the Caribbean, Central and 
South America network for HIV epidemiology (CCASAnet),10 IeDEA Southern Africa,11 and 
IeDEA Asia-Pacific.12 For the IeDEA Southern Africa region, we restricted the analysis to two 
cohorts from South Africa that reduced under-reporting of cancer cases in the HIV cohorts 
through record linkages with the National Cancer Registry.13 COHERE is a collaboration of 
observational HIV cohorts across Europe.14 It contributed data from 24 cohorts, covering 36 
countries. All cohorts obtained ethical approval from local ethics committees or institutional 
review boards, and the Cantonal Ethics Committee of Bern (number 028/2015) also granted 
ethical approval for this study. 
Inclusion criteria and definitions 
We restricted the analysis to cohorts that systematically collected cancer data or had 
enhanced their data through record linkages with cancer registries. We included women living 
with HIV who started ART after 1995 at 16 years or older. We excluded women who started 
ART before enrolment into cohort, women without follow-up after ART initiation, and women 
without any CD4 cell count measurements at ART initiation or during follow-up. We also 
excluded cohorts with less than 100 eligible women and the Asia-Pacific region because of 
small sample size (post-hoc decision). We analyzed ICC cases diagnosed any time after ART 
initiation as incident cases and excluded women diagnosed with ICC before or at ART initiation 
(prevalent ICC cases) from the analysis. We defined ART as a combination of at least three 
antiretroviral drugs from any class, including protease inhibitors (PIs), nucleoside reverse 
transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors (NNRTIs). We 
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assumed that women remained on ART and did not consider treatment interruptions and 
terminations. CD4 cell count at ART initiation was defined as the cell count closest to ART 
initiation, during the period within 180 days before to seven days after initiation.  
Statistical analyses 
We calculated raw ICC incidence rates by dividing the number of incident ICC cases by 
person-years (pys) at risk. Time at risk was measured from ART initiation to ICC diagnosis, last 
follow-up visit, death, or database closure, whichever happened first. We used proportional 
hazard flexible parametric survival models15 to estimate regional ICC incidence rates and to 
identify risk factors for developing ICC. We compared ICC rates at 2 years and 5 years after 
ART initiation across geographic regions. We used restricted cubic splines with 4 degrees of 
freedom and allowed for time-dependent region-effects with 2 degrees of freedom to model 
the baseline hazard. We performed likelihood ratio tests to test interactions between risk 
factors and regions. We assessed the following potential risk factors in the analysis: age at ART 
initiation (16-30, 31-50, >50 years); first-line ART regimen (NNRTI-based, PI-based, other); 
calendar period of ART initiation (1996-1998, 1999-2003, 2004-2007, 2008-2014); CD4 cell 
count at ART initiation; and current (time-updated) CD4 cell count. We treated CD4 cell count 
at ART initiation and current CD4 cell count as continuous variables. Analyses including CD4 
cell count at ART initiation were restricted to women with available data on this variable. HIV 
RNA load at ART initiation was assessed in descriptive analyses.  
We fit a crude model that included only the time-dependent region-effects, resulting 
in region-specific baseline hazards, and no other risk factors. The main adjusted model 
included region, CD4 cell count at ART initiation, age at ART initiation, first-line ART regimen, 
and calendar period of ART initiation. From the main adjusted model, we predicted ICC 
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incidence rates for women with a specific set of risk factors, i.e. for women who initiated an 
NNRTI-based regimen between 2008-2014 at age 31-50 years with a CD4 cell count of 200 
cells/µl. In a sensitivity analysis, the adjusted model included current (time-updated) CD4 cell 
count instead of CD4 cell count at ART initiation. In a second sensitivity analysis, we excluded 
ICC cases diagnosed within the first three months after ART initiation as prevalent cases and 
women with less than three months of follow-up. Results are presented as medians with 
interquartile ranges (IQR), number and percentages of women, incidence rates per 100,000 
pys and hazard ratios (HRs) with 95% confidence intervals (CIs). We used Stata 14 (Stata 
Corporation, College Station, Texas, USA) and R (R Foundation, Vienna, Austria) for our 
analyses. 
 
Results 
Descriptive analyses 
The merged dataset included information on 126,063 women living with HIV. We 
excluded 44,419 women because they did not receive ART and another 14,413 women for 
reasons detailed in Supplementary Figures S1-S5. We made a post-hoc decision to exclude the 
Asia-Pacific region because too few eligible women remained after applying our exclusion 
criteria.  
We included data on 64,231 women living with HIV, drawn from 36 cohorts and 45 
countries across Europe, North America, Latin America, and South Africa (Figure 1). Overall, 
median age at ART initiation was 34.9 years (IQR 29.3-41.9), and was higher in North America 
(38.6 years) than in other regions (Table 1). Median CD4 cell count at ART initiation was 115 
cells/µl (IQR 50-182) in South Africa, 178 cells/µl (IQR 74-281) in Latin America, and 241 
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cells/µl in both North America and Europe (Table 1). In South Africa, less than 1% of women 
started ART before 2004, but 26% of women in Latin America, 40% in Europe and 70% in North 
America initiated ART between 1996 and 2003. Most women in South Africa (93%) and Latin 
America (70%) received an NNRTI-based first-line regimen, but the majority of women in the 
European (55%) and North American (60%) cohorts received a PI-based first-line regimen. 
Median follow-up after ART initiation was around 5 years in Europe, North, and Latin America, 
but shorter in South Africa (2.1 years). 
Over 320,141 pys of follow-up, 356 incident ICC cases were diagnosed (164 in Europe, 
156 in South Africa, 19 in North America, and 17 in Latin America). In women who developed 
ICC, median time from ART initiation to ICC diagnosis was 1.9 years (IQR 0.7-4.2), and it ranged 
from 1.7 years in South Africa and North America to 2.6 years in Latin America (Supplementary 
Table S1). Median age at ICC diagnosis was 33 years in Latin America, and 38-40 years in South 
Africa, North America, and Europe. Median CD4 cell count at ICC diagnosis ranged from 275 
cells/µl in Latin America to 370 cells/µl in North America.  
Comparing ICC risk across regions 
The raw ICC incidence rate was highest in South Africa, with 447/100,000 pys (95% CI 
382-523), followed by Latin America (136/100,000 pys; 95% CI 85-219), North America 
(76/100,000 pys; 95% CI 48-119), and Europe (66/100,000 pys; 95% CI 57-77). In Europe, North 
America, and Latin America, there was some evidence for a decrease in crude and adjusted 
ICC incidence rates after more than one year on ART, except in South Africa (Figure 2). In crude 
analyses, ICC rates at 5 years after ART initiation were 11-times higher in women living with 
HIV in South Africa than in their European counterparts (HR 11.06, 95% CI 7.80-15.68). The 
much higher ICC rate in South African women was not explained by differences in CD4 cell 
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count at ART initiation, age at ART initiation, first-line ART regimen, or calendar period of ART 
initiation (adjusted HR [aHR] 10.66, 95% CI 6.73-16.88; see Table 2). In crude (HR 2.32, 95% CI 
1.24-4.31) and adjusted analyses (aHR 2.43, 95% CI 1.27-4.68), ICC rates at 5 years after ART 
initiation were more than twice as high in Latin American as in European women. In North 
American and European women, ICC rates after ART initiation were comparable in crude (HR 
0.98, 95% CI 0.48-1.99) and adjusted analyses (aHR 0.79, 95% CI 0.37-1.71). The regional 
comparisons of ICC rates were similar at 2 years after ART initiation (Table 2). Also at 2 years 
after ART initiation, ICC rates were much higher in South Africa than in Europe (aHR 6.23, 95% 
CI 4.29-9.05). When we excluded ICC cases diagnosed within the first three months after ART 
initiation in a sensitivity analysis, results did not meaningfully change (Supplementary Table 
S2). 
Risk factors for incident ICC  
We did not find evidence of regional variation in the effect of CD4 cell count at ART 
initiation, age at ART initiation, first-line ART regimen, or calendar period of ART initiation on 
the risk of developing ICC (all p-values for interaction ≥ 0.13, see Table 3). Across all regions 
combined, the risk of developing ICC increased among women who initiated ART at lower CD4 
cell counts (per 100 cell/µl decrease, aHR 1.25, 95% CI 1.15-1.36), and with older age at ART 
initiation (>50 years versus 16-30 years, aHR 1.57, 95% CI 1.03-2.40). There was no association 
between type of first-line ART regimen and the risk of developing incident ICC (PI-based versus 
NNRTI-based, aHR 1.05, 95% CI 0.79-1.41), and we did not observe a relevant decline in ICC 
rates by calendar period of ART initiation. The effects of the risk factors assessed in the main 
adjusted model remained similar when we excluded ICC cases diagnosed within the first three 
months after ART initiation from the analysis (Supplementary Table S3). 
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In a sensitivity analysis, we assessed the effect of current CD4 cell count on the risk of 
developing ICC and found that it varied across regions (p-value for interaction = 0.017). In 
analyses adjusted for age, first-line ART regimen, and calendar period of ART initiation, we did 
not find an association between current CD4 cell count and risk of developing ICC in South 
Africa (per 100 cells/µl decrease, aHR 1.00, 95% CI 0.92-1.10) or North America (aHR 1.08, 95% 
CI 0.90-1.30). However, a decrease of 100 cells/µl in current CD4 cell count increased the risk 
of developing ICC by 18% in European women (aHR 1.18, 95% CI 1.10-1.27) and 41% in Latin 
American women (aHR 1.41, 95% CI 1.07-1.86; see Supplementary Table S4 and 
Supplementary Figure S6).  
 
Discussion 
Across geographic regions, we found large inequities for cervical cancer incidence in 
women living with HIV. ICC incidence rates were high in women living with HIV in all regions 
studied, but the risk of developing ICC was much higher in women who had initiated ART in 
South Africa or Latin America than in women who had initiated ART in Europe or North 
America. Across all regions combined, the risk of developing ICC increased with older age and 
lower CD4 cell counts at ART initiation.  
We believe this is the first study to provide a comparison of ICC incidence rates among 
women living with HIV across several geographic regions. To improve comparability of results 
across regions, we applied the same inclusion criteria and statistical methods across the whole 
dataset. With more than 60,000 women and 356 ICC cases included, this is also the largest 
study of ICC incidence in women living with HIV. However, several limitations of our study 
need to be acknowledged. Less than 20 ICC cases each were recorded in Latin America and 
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North America. Thus, our comparison of ICC rates between those regions and Europe are of 
limited precision. ICC case identification and validation are likely to vary across regions and 
may have affected observed regional differences in ICC rates. Our results for South Africa may 
not be generalizable to Southern Africa as a region, given that we restricted our analyses to 
two urban cohorts in South Africa, which had been linked with the National Cancer Registry 
to reduce under-reporting of ICC cases. Because we included all women who started ART, 
irrespective of whether they remained in treatment, our results may not be representative of 
women who stayed continuously on ART. HIV RNA measurements at ART initiation were 
missing for one-third of women included in Latin America, and almost 80% of women from 
South Africa. Therefore, we could not use HIV RNA load to evaluate treatment response over 
time. Information on duration of HIV infection, HPV co-infection status, cervical cancer 
screening history, and smoking status was generally not available. Thus, we could not explore 
their effects on the risk of being diagnosed with ICC or adjust the regional comparisons for 
these potential confounders. Furthermore, as data on history of hysterectomy were not 
available, we could not exclude women who were no longer at risk of developing ICC. It would 
also have been interesting to assess ICC-related inequities in more depth, but we did not have 
data on ICC stage at diagnosis, for example. 
We found that across all regions women living with HIV were at high risk of developing 
ICC after ART initiation. Most previous studies did not restrict their analyses to women who 
had initiated ART, but rather report ICC incidence estimates for women living with HIV 
irrespective of ART use.6,16-18 The raw ICC incidence rates in women living with HIV who had 
initiated ART, ranging from 66/100,000 pys in Europe to 447/100,000 pys in South Africa, were 
substantially higher than the ICC incidence rates reported for women from the general 
population in the included regions (≤30/100,000 pys).2 In our study, ICC rates after ART 
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initiation were by far highest in South Africa, followed by Latin America, and they were lower 
in women who had started ART in North America or Europe. These findings corroborate the 
regional ICC incidence rate pattern in the general population,2 but the difference between 
South Africa and other regions is even more pronounced among women living with HIV.  
The high ICC incidence rates we found in women from South Africa are similar to ICC 
incidence rates in women living with HIV in the United States in the early 1990s.7 In the United 
States, ICC incidence rates in women living with HIV had already dropped in the mid-1990s, 
before ART became available, and this drop has partly been attributed to better screening and 
more effective treatment of pre-cancerous cervical lesions.7 The extent to which ART protects 
women living with HIV from developing ICC is still being explored. Although ART reduces the 
prevalence of high-risk HPV in women living with HIV and promotes regression of cervical 
lesions,8 many women in our analyses, notably in South Africa, may have started ART too late, 
when potentially irreversible pre-cancerous cervical lesions were already present. 
Furthermore, not all women in our study would have achieved sustained suppression of HIV 
RNA, and high HIV RNA loads have been associated with an increased risk of HPV infection and 
cervical pre-cancerous lesions.19 Low CD4 cell counts have also been associated with a higher 
risk of HPV infection3 and development of severe cervical lesions.20 Accordingly, several 
studies showed an increased ICC risk in women with low nadir,21 baseline,18 or current CD4 
cell counts.17 It remains a matter of debate at what stage of cervical carcinogenesis the effect 
of HIV-related immunodeficiency is largest. Across all regions combined, we found that the 
risk of developing ICC increased in women who initiated ART at low CD4 cell counts. High 
current CD4 cell counts had a protective effect in Latin America and Europe, but not in North 
America and South Africa. 
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Our analyses revealed massive regional differences in ICC rates in women living with 
HIV. Several factors could account for this finding. HPV prevalence in women living with HIV 
in sub-Saharan Africa or Latin America is higher than in North America or Europe,22 and this 
may contribute to the increased ICC burden in South African and Latin American women living 
with HIV. Women in South Africa and Latin America also tended to initiate ART at lower CD4 
cell counts than women in Europe, and low CD4 cell counts at ART initiation increased the risk 
of developing ICC. Nevertheless, in our analyses large regional differences in ICC rates 
persisted after adjusting for CD4 cell counts. Therefore, inequities in access to effective 
cervical cancer screening and treatment of pre-cancerous cervical lesions are likely to be the 
main driver of regional variation in ICC rates in women living with HIV. Substantial global 
efforts are needed to improve cervical cancer screening and treatment for women living with 
HIV, and to promote national HPV vaccination programmes. Unfortunately, most Southern 
African countries and some regions of Latin America lack the resources to treat ICC.23,24  
The availability of HPV vaccination and the long natural history from HPV infection 
through cervical intraepithelial neoplasia to invasive cancer make ICC particularly amenable 
to primary and secondary prevention.25 However, it has been estimated that in 2014 less than 
one-third of female adolescents aged 10-20 years in high-income countries and only 1% in 
low-income countries had received the full course of HPV vaccine.26 At present, data on HPV 
vaccination coverage among women living with HIV are lacking.27 Access to screening services 
with early detection and treatment of pre-cancerous cervical lesions remains key for ICC 
prevention in women living with HIV. However, there are extensive regional differences in 
access to effective cervical cancer screening. Less than 10% of women living in low-income 
countries have access to effective cervical cancer screening as compared to more than 60% in 
high-income countries.28 Integrating cervical cancer screening services into established HIV 
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care programmes may facilitate screening access for women living with HIV and improve 
sustainability of screening programmes.29 Yet, it remains unclear how many women living with 
HIV actually receive regular screening for pre-cancerous cervical lesions. HIV cohorts and 
integrated cervical cancer screening services often do not systematically collect patient-level 
data on screening and treatment of pre-cancerous cervical lesions.30 Rigorous patient-level 
monitoring of cervical cancer screening and treatment programmes is essential to identify 
coverage gaps and target interventions.30 
Conclusion 
Our finding that women living with HIV who initiated ART in South Africa or Latin 
America were at much higher risk of developing ICC than women in North America or Europe 
reveals drastic global health inequities. ICC prevention through early ART initiation and scale 
up of effective cervical cancer screening services for women living with HIV, alongside the 
promotion of global access to HPV vaccination should be key parts of international efforts to 
reduce cancer-related health inequities.  
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Table 1: Characteristics of included women at ART initiation. 
 South Africa Latin America North America Europe 
 N (%) N (%) N (%) N (%) 
All women 13,569 (100%) 2,261 (100%) 4,120 (100%) 44,281 (100%) 
Median follow-up 
time (IQR) [years] 2.1 (0.8-4.1) 5.0 (2.1-8.5) 5.4  (2.3-9.9) 4.8  (2.0-8.5) 
Median age at 
ART initiation 
(IQR) [years] 
35.1 
(29.7-41.7) 
35.4 
(29.3-43.6) 
38.6 
(32.4-44.8) 
34.6 
(29.0-41.5) 
Age at ART 
initiation [years]     
   16-30 3,584 (26%) 627 (28%) 693 (17%) 12,934 (29%) 
   31-50 8,969 (66%) 1,363 (60%) 2,947 (72%) 26,944 (61%) 
    >50 1,016 (7%) 271 (12%) 480 (12%) 4,403 (10%) 
First-line ART 
regimen 
    
   NNRTI-based 12,594 (93%) 1,579 (70%) 1,261 (31%) 16,724 (38%) 
   PI-based 939 (7%) 623 (28%) 2,476 (60%) 24,325 (55%) 
   Other ART 36 (<1%) 59 (3%) 383 (9%) 3,232 (7%) 
Year of ART 
initiation     
   1996-1998 0 (0%) 26 (1%) 1,600 (39%) 4,260 (10%) 
   1999-2003 51 (<1%) 560 (25%) 1,276 (31%) 13,236 (30%) 
   2004-2007 6,791 (50%) 801 (35%) 864 (21%) 12,821 (29%) 
   2008-2014 6,727 (50%) 874 (39%) 380 (9%) 13,964 (32%) 
Median CD4 cell 
count  at ART 
initiation (IQR) 
[cells/µl] 
115 
(50-182) 
178 
(74-281) 
241 
(107-385) 
241 
(129-363) 
CD4 cell count at 
ART initiation 
[cells/µl] 
    
   < 50  3,113  (23%) 340 (15%) 577 (14%) 4,676  (11%) 
   50-99 2,402  (18%) 274 (12%) 303 (7%) 3,271   (7%) 
   100-199 4,733  (35%) 465 (21%) 663 (16%) 7,890  (18%) 
   200-349 1,821  (13%) 601 (27%) 1,047 (25%) 13,122  (30%) 
   350-499 276   (2%) 154 (7%) 587 (14%) 6,146  (14%) 
   500-699 139   (1%) 74 (3%) 349 (8%) 3,069   (7%) 
   ≥ 700 66   (<1%) 30 (1%) 170 (4%) 1,638   (4%) 
   Missing 1,019   (8%) 323 (14%) 424 (10%) 4,469  (10%) 
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ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI, 
non-nucleoside reverse-transcriptase inhibitor; PI, protease-inhibitor; RNA, ribonucleic acid.  
 
 
  
Median HIV RNA  
at ART initiation 
(IQR) [log10 
/  
4.4 
(2.6-5.2) 
4.8 
(4.0-5.3) 
4.3 
(3.4-5.0) 
4.5 
(3.7-5.1) 
HIV RNA at ART 
initiation  
[log10 copies/ml] 
    
   < 2.7 788 (6%) 91 (4%) 608 (15%) 4,704  (11%) 
   2.7-3.9 404 (3%) 260 (11%) 806 (20%) 7,319  (17%) 
   4.0-4.9 870   (6%) 
 
585 (26%) 1,218 (30%) 14,051  (32%) 
   ≥ 5.0 984 (7%) 568 (25%) 946 (23%) 11,764 (27%) 
   Missing 10,523 (78%) 757 (33%) 542 (13%) 6,443 (15%) 
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Table 2: Comparison of ICC rates between different regions and Europe: Crude and adjusted HRs for 
ICC at 2 years and 5 years after ART initiation in women living with HIV. 
* Adjusted for CD4 cell count at ART initiation, age at ART initiation, first-line ART regimen, and 
calendar period of ART initiation.  
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; ICC, invasive cervical cancer. 
  
 At 2 years At 5 years 
 Crude HR  
(95% CI) 
Adjusted HR* 
(95% CI) 
Crude HR  
(95% CI) 
Adjusted HR*  
(95% CI) 
Region     
   Europe 1.00 1.00 1.00 1.00 
   North America 1.81 (0.94 - 3.48) 
 
1.51 (0.73 – 3.12) 
 
0.98 (0.48 - 1.99) 
 
0.79 (0.37 - 1.71) 
    Latin America 1.93 (1.09 - 3.42) 
 
1.83 (0.99 - 3.37) 
 
2.32 (1.24 - 4.31) 
 
2.43 (1.27 - 4.68) 
    South Africa 6.84 (5.20 - 9.00) 
 
6.23 (4.29 - 9.05) 
 
11.06 (7.80 - 15.68) 
 
10.66 (6.73 - 16.88) 
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Table 3: Adjusted hazard ratios for the effect of different factors on the risk of developing incident 
ICC in women who have initiated ART. 
 Hazard ratio* p-value for  
  (95% CI) interaction** 
CD4 cell count at ART initiation   0.76 
   per 100 cells/µl decrease 1.25 (1.15 - 1.36)  
Age at ART initiation [years]  0.34 
   16-30 1.00  
   31-50 1.38 (1.05 - 1.81)  
   >50 1.57 (1.03 - 2.40)  
First-line ART regimen  0.21 
   NNRTI-based 1.00  
   PI-based 1.05 (0.79 - 1.41)  
   Other ART 0.57 (0.27 - 1.18)  
Year of ART initiation  0.13 
   1996-1998 1.49 (0.92 - 2.42)  
   1999-2003 1.19 (0.80 - 1.77)  
   2004-2007 0.83 (0.61 - 1.14)  
   2008-2014 1.00  
* Adjusted for region, CD4 cell count at ART initiation, age at ART initiation, calendar year of ART 
initiation, and first-line ART regimen. 
** Derived from likelihood ratio test comparing the adjusted model with and without the interaction 
of a specific variable with region. 
ART, antiretroviral therapy; CI, confidence interval; ICC, invasive cervical cancer; NNRTI, non-
nucleoside reverse-transcriptase inhibitor; PI, protease-inhibitor
28 
 
 
Figure 1: Map of countries that contributed cohort data; number of included women, by country.  
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Figure 2: Regional ICC incidence rates with 95% confidence intervals by time since ART initiation, 
predicted from the crude model (red) and the main adjusted model (blue) for women who initiated 
an NNRTI-based regimen between 2008-2014, at age 31-50 years, with a CD4 cell count of 200 
cells/µl. 
 
ART, antiretroviral therapy; ICC, invasive cervical cancer; NNRTI, non-nucleoside reverse-
transcriptase inhibitor; pys, person-years. 
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Supplementary Figure S1: Identification of study population for analysis. The flow diagram shows the 
number of included and excluded women. 
 
 
ART, antiretroviral therapy;  ICC, invasive cervical cancer. 
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Supplementary Figure S2: Identification of study population for the European region. 
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Supplementary Figure S3: Identification of study population for the North American region. 
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Supplementary Figure S4: Identification of study population for the Latin American region. 
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Supplementary Figure S5: Identification of study population for the South African region. 
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Supplementary Figure S6:  ICC incidence rates by time since ART initiation and current CD4 cell count 
(cells/µl) predicted from the second adjusted model (sensitivity analysis) for women living with HIV 
who initiated an NNRTI-based first-line ART regimen between 2008-2014 at age 31-50 years. 
 
ART, antiretroviral therapy;   ICC,   invasive cervical cancer; NNRTI, non-nucleoside reverse-
transcriptase inhibitor. 
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Supplementary Table S1: Characteristics of women with incident ICC.  
ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI, 
non-nucleoside reverse-transcriptase inhibitors; PI, protease-inhibitors; RNA, ribonucleic acid.  
  
 South Africa Latin America North America Europe 
 N (%) N (%) N (%) N (%) 
All ICC cases 156 (100%) 17 (100%) 19 (100%) 164 (100%) 
Median time to ICC 
diagnosis (IQR) [years]    1.7   (0.9-3.2)    2.6   (0.7-5.6)    1.7   (1.2-6.0)    2.2   (0.7-5.3) 
Median age at ICC 
diagnosis (IQR) [years] 
  38.3 
(33.5;  42.7) 
  33.0   
(28.8;  43.4) 
 
  39.0   
(29.6;  43.1) 
 
  39.7   
(33.8;  45.4) 
 Age at ICC diagnosis 
[years]    
 
   16-30        13   (8%)      5  (29%) 5 (26%)        16  (10%)      
   31-50       131  (84%)      10  (59%) 13 (68%)       124  (76%)      
    >50        12   (8%)      2  (12%) 1 (5%)        24  (15%)      
First-line ART regimen     
   NNRTI-based 150  (96%) 14  (82%) 3  (16%) 55  (34%) 
   PI-based 5   (3%) 3  (18%) 15  (79%) 103  (63%) 
   Other ART 1   (1%) 0   (0%) 1   (5%) 6   (4%) 
Year of ART initiation     
   1996-1998         0   (0%)             1   (6%)             10  (53%)              36  (22%)      
   1999-2003         0   (0%)             6  (35%)              6  (32%)              71  (43%)      
   2004-2007       114  (73%)             3  (18%)              3  (16%)              31  (19%)      
   2008-2014        42  (27%)             7  (41%)              0   (0%)              26  (16%)      
Median CD4 cell count  at 
ICC diagnosis (IQR) 
[cells/µl] 
 292 (170-450)  275 (190-406)  370 (200-586)  350 (183-523) 
Women with missing CD4 
cell count at ICC diagnoisis        37  (24%)             6  (35%)              1   (5%)              23  (14%)      
Median HIV RNA at ICC 
diagnosis (IQR) [log10 
copies/ml] 
   1.7   (1.7-1.7)    1.7   (1.6-3.3)    2.3   (2.3-2.8)    2.0   (1.7-3.7) 
Women with missing HIV 
RNA at ICC diagnosis        51  (33%)             4  (24%)              1   (5%)              31  (19%)      
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Supplementary Table S2: Comparison of ICC rates between different regions and Europe: Crude 
and adjusted HRs for ICC at 2 years and 5 years after ART initiation in women living with HIV; 
sensitivity analysis excluding ICC cases diagnosed within the first three months after ART initiation. 
* Adjusted for CD4 cell count at ART initiation, age at ART initiation, first-line ART regimen, and 
calendar period of ART initiation.  
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; ICC, invasive cervical cancer. 
  
 At 2 years At 5 years 
 Crude HR  
(95% CI) 
Adjusted HR* 
(95% CI) 
Crude HR  
(95% CI) 
Adjusted HR*  
(95% CI) 
Region     
   Europe 1.00 1.00 1.00 1.00 
   North America 1.31 (0.71 - 2.41) 
 
1.09 (0.55 - 2.15) 
 
0.99 (0.49 – 2.01) 
 
0.80 (0.37 - 1.74) 
    Latin America 1.81 (1.02 - 3.24) 
 
1.94 (0.98 - 3.82) 
 
2.32 (1.23 - 4.39) 
 
2.42 (1.22 - 4.78) 
    South Africa 7.36 (5.52 - 9.83) 
 
6.85 (4.60 - 10.19) 
 
10.53 (7.08 - 15.67) 
 
9.87 (5.89 - 16.53) 
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Supplementary Table S3: Sensitivity analysis of risk factors for incident ICC in women who have 
initiated ART, excluding ICC cases diagnosed within the first three months after ART initiation. 
 Hazard ratio* 
  (95% CI) 
CD4 cell count at ART initiation   
   per 100 cells/µl decrease 1.23 (1.12 - 1.34) 
Age at ART initiation [years]  
   16-30 1.00 
   31-50 1.32 (1.00 - 1.76) 
   >50 1.48 (0.94 - 2.33) 
First-line ART regimen  
   NNRTI-based 1.00 
   PI-based 1.07 (0.79 - 1.45) 
   Other ART 0.39 (0.16 - 0.97) 
Year of ART initiation  
   1996-1998 1.71 (1.01 - 2.90) 
   1999-2003 1.37 (0.88 – 2.13) 
   2004-2007 0.98 (0.69 - 1.39) 
   2008-2014 1.00 
* Adjusted for region, CD4 cell count at ART initiation, age, calendar year of ART start, and first-line 
ART regimen. 
** Derived from likelihood ratio test comparing the adjusted model with and without the interaction 
of a specific variable with region. 
ART, antiretroviral therapy; CI, confidence interval; ICC, invasive cervical cancer; NNRTI, non-
nucleoside reverse-transcriptase inhibitor; PI, protease-inhibitor 
  
 
41 
 
Supplementary Table S4: Sensitivity analysis of risk factors for incident ICC in women who have 
initiated ART, including current CD4 cell count instead of CD4 cell count at ART initiation. 
 Hazard ratio* p-value for  
  (95% CI) interaction** 
Current CD4 cell count per 100 
cells/µl decrease  
 0.017 
   South Africa 1.00 (0.92 - 1.10)  
   Latin America 1.41 (1.07 - 1.86)  
   North America 1.08 (0.90 – 1.30)  
   Europe 1.18 (1.10 - 1.27)  
Age at ART initiation [years]  0.055 
   16-30 1.00  
   31-50 1.39 (1.07 - 1.81)  
   >50 1.54 (1.02 - 2.32)  
First-line ART regimen  0.103 
   NNRTI-based 1.00  
   PI-based 1.01 (0.77 - 1.33)  
   Other ART 0.48 (0.23 - 1.00)  
Year of ART initiation  0.129 
   1996-1998 1.46 (0.92 - 2.32)  
   1999-2003 1.14 (0.77 - 1.66)  
   2004-2007 0.84 (0.62 - 1.13)  
   2008-2014 1.00  
* Adjusted for current CD4 cell count and its interaction with region, age, calendar year of ART start, 
and first-line ART regimen. 
** Derived from likelihood ratio test comparing the adjusted models with and without the 
interaction of a specific variable with region. 
ART, antiretroviral therapy; CI, confidence interval; ICC, invasive cervical cancer; NNRTI, non-
nucleoside reverse-transcriptase inhibitor; PI, protease-inhibitor 
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